Antibodies against claudin 18.2 useful in cancer diagnosis
The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
1. An antibody or antigen-binding fragment thereof that binds to claudin 18.2 (CLDN18.2) or a peptide fragment thereof, wherein said peptide fragment comprises the amino acid sequence TEDEVQSYPSKHDYV (SEQ ID NO: 5) or EVQSYPSKHDYV (SEQ ID NO: 6) wherein the antibody or the antigen-binding fragment thereof comprises
(i) an antibody heavy chain variable region comprising:
a CDR1 having the amino acid sequence set forth in SEQ ID NO: 8,
a CDR2 having the amino acid sequence set forth in SEQ ID NO: 9, and
a CDR3 having the amino acid sequence set forth in SEQ ID NO: 10; and
(ii) an antibody light chain variable region comprising:
a CDR1 having the amino acid sequence set forth in SEQ ID NO: 12,
a CDR2 having the amino acid sequence set forth in SEQ ID NO: 13, and
a CDR3 having the amino acid sequence set forth in SEQ ID NO: 14.
2. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, and an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.
3. A method for treating cancer in a subject, the method comprising:
(i) identifying a subject as having cancer cells expressing CLDN18.2 based on detection of a signal indicative of the formation of a complex between the antibody or the antigen-binding fragment thereof of claim 1 and CLDN18.2 or the peptide fragment thereof from a cellular sample from the subject; and
(ii) administering a therapeutic anti-CLDN18.2 antibody to the subject.
4. The method of claim 3 , wherein the cellular sample comprises a paraffin embedded tissue section fixed with paraformaldehyde.
5. A method for treating cancer in a subject, comprising administering a therapeutic anti-CLDN18.2 antibody to the subject, wherein prior to the administration of the therapeutic anti-CLDN18.2 antibody a cellular sample from the subject has been contacted with the antibody or the antigen-binding fragment thereof of claim 1 to determine CLDN18.2 expression by cells in the cellular sample.
6. The method of claim 5 , wherein the cellular sample comprises a paraffin embedded tissue section fixed with paraformaldehyde.
7. A diagnostic test kit, the kit comprising the antibody or the antigen-binding fragment thereof of claim 1 .
8. The method of claim 5 , wherein said cancer is gastric, esophageal, pancreatic, ear nose and throat (ENT), lung, ovarian, colon, hepatic, head-neck, or gallbladder cancer.
9. A method for detecting CLDN18.2 or determining the quantity of CLDN18.2 in a sample comprising the steps of:
(i) contacting a sample with the antibody or the antigen-binding fragment thereof of claim 1 ; and
(ii) detecting the formation of a complex or determining the quantity of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 or the peptide fragment thereof.
10. A method for determining whether cells express CLDN18.2 comprising the steps of:
(i) contacting a cellular sample with the antibody or the antigen-binding fragment thereof of claim 1 ; and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 or the peptide fragment thereof expressed by cells in said sample.
11. The method of claim 10 , wherein said sample is derived from a subject having cancer or suspected of having cancer.
12. The method of claim 11 , wherein said cancer is gastric, esophageal, pancreatic, ear nose and throat (ENT), lung, ovarian, colon, hepatic, head-neck, or gallbladder cancer.
13. A method for diagnosis, detection or monitoring of cancer comprising the steps of:
(i) contacting a biological sample with the antibody or the antigen-binding fragment thereof of claim 1 ; and
(ii) detecting the formation of a complex and/or determining the quantity of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 or the peptide fragment thereof,
wherein the presence of the complex indicates the onset, presence, progression, or recurrence of cancer.
14. The method of claim 13 , wherein said cancer is gastric, esophageal, pancreatic, ear nose and throat (ENT), lung, ovarian, colon, hepatic, head-neck, or gallbladder cancer.
15. A method for determining whether a cancer is treatable by a cancer therapy targeting CLDN18.2 comprising the steps of:
(i) contacting a sample comprising cancer cells with the antibody or the antigen-binding fragment thereof of claim 1 ; and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 or the peptide fragment thereof,
wherein the presence of the complex indicates that the cancer is treatable by a cancer therapy targeting CLDN18.2.
16. The method of claim 15 , wherein said cancer is gastric, esophageal, pancreatic, ear nose and throat (ENT), lung, ovarian, colon, hepatic, head-neck, or gallbladder cancer.